Daily BriefsIndia

India: Apl Apollo Tubes, Motherson Sumi Systems, Ipca Laboratories, Abbott India and more

In today’s briefing:

  • India Channel Insight #23 | APL Apollo, Kajaria, Somany
  • Motherson Sumi Systems: Mega-Restructuring to Materialise, New SAMIL Arrives
  • Ipca Laboratories: Two for One Share Stock Split
  • Pick of the Week: Abbott India Ltd

India Channel Insight #23 | APL Apollo, Kajaria, Somany

By Pranav Bhavsar


Motherson Sumi Systems: Mega-Restructuring to Materialise, New SAMIL Arrives

By ICICI Securities Limited

  • Motherson Sumi (MSSL) primarily serves global PV & CV industry with a history of successful turnarounds in acquisitions and inorganic-led growth.
  • MSSL’s stock price has grown at ~13% CAGR from ~Rs 145 levels in January 2017, widely outperforming the Nifty Auto index
  • We value the combined entity post-merger of erstwhile SAMIL into MSSL at Rs 270/share on SOTP basis
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Ipca Laboratories: Two for One Share Stock Split

By ICICI Securities Limited

  • The Ipca Laboratories stock has been sub-divided from one existing equity share of Rs 2 each face value into two equity shares of Rs 1 each face value
  • Consequently, Ipca Lab’s share price has dropped to ~Rs 1099/share from ~Rs 2200/share.
  • Hence, our target price has also now been revised to Rs 1245/share post this corporate action.
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pick of the Week: Abbott India Ltd

By Axis Direct

  • Revenue growth of Abbott India Ltd (AIL) for FY21 has outpaced the Indian Pharma Market (IPM) growth by 100 bps majorily contributed by addition of new products
  • AIL has leadership position in 9 top brands out of 10 in their respective therapies
  • We recommend BUY with a TP of Rs 20,000/share.
Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Before it’s here, it’s on Smartkarma